Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Self-assembling nanocomplexes by combining ferumoxytol, heparin and protamine for cell tracking by magnetic resonance imaging.
Diplomatic Assistance: Can Helminth-Modulated Macrophages Act as Treatment for Inflammatory Disease?
Quantification of normal-appearing white matter tract integrity in multiple sclerosis: a diffusion kurtosis imaging study.
International Joint Israel-Greek-Italian Neuroimmunological meeting
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis.
Defining the Role of Physiotherapy in Palliative Care in Multiple Sclerosis.
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis.
Developmental Origin of Oligodendrocyte Lineage Cells Determines Response to Demyelination and Susceptibility to Age-Associated Functional Decline.
Autoimmune sleep disorders.
Multiple sclerosis: Could Helicobacter pylori provide protection against multiple sclerosis?
Policy: NIH to balance sex in cell and animal studies.
UCSF Seminar: "Imaging spinal cord gray matter atrophy in MS using SF-SIGMA. Is neuronal loss a key mediator of MS disability?"
Multiple Sclerosis: Modulation of Toll-Like Receptor (TLR) Expression by Interferon-β Includes Upregulation of TLR7 in Plasmacytoid Dendritic Cells.
A study to evaluate the effect of ultrasound treatment on nodules in multiple sclerosis patients.
Optimal combination of FLAIR and T2-weighted MRI for improved lesion contrast in multiple sclerosis.
Recent insights into the mechanism of action of glatiramer acetate.
24th Biennial Meeting ISN/ASN 2013
VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis.
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
Risk factors for convertion to clinically defined multiple sclerosis after clinically isolated syndrome in a racially mixed Brazilian cohort.
Evaluation of quality of life and fatigue in radiologically isolated syndrome.
Treatment Burden and Chronic Illness: Who is at Most Risk?
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

Pages